Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23718561 | 1.00 | F2 (0.31) | F2MAPTKMT2ATNIKALDH1A1 | |
| SCHEMBL25144054 | 0.84 | LMNA (0.36) | F2MAPTKMT2AALDH1A1LMNA | |
| SCHEMBL23704429 | 0.84 | — | — | |
| SCHEMBL30097402 | 0.83 | F2 (0.31) | F2TNIKALDH1A1LMNAHSD17B10 | |
| SCHEMBL23711797 | 0.83 | ALDH1A1 (0.30) | ALDH1A1LMNAHSD17B10 | |
| SCHEMBL23711611 | 0.83 | F2 (0.31) | F2TNIKALDH1A1LMNAHSD17B10 | |
| SCHEMBL30116795 | 0.76 | SLC29A1 (0.40) | ALDH1A1LMNA | |
| SCHEMBL28878914 | 0.74 | LMNA (0.31) | F2MAPTALDH1A1LMNAHSD17B10 | |
| SCHEMBL30097410 | 0.72 | F2 (0.32) | F2MAPTKMT2ATNIKALDH1A1 | |
| SCHEMBL23711614 | 0.70 | PIK3C3 (0.40) | KMT2AALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230140430-A1 | 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS | BRISTOL-MYERS SQUIBB COMPANY | 2023-05-04 | — | — | US | disclosed |
| US-20230127326-A1 | C3-SUBSTITUTED 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS | BRISTOL-MYERS SQUIBB COMPANY | 2023-04-27 | — | — | US | disclosed |
| US-20230122249-A1 | 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-04-20 | — | — | US | disclosed |
| EP-4097107-A1 | C3-SUBSTITUTED 1H-PYRAZOLO[4,3-D]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS | Bristol-Myers Squibb Company (US) | 2022-12-07 | — | — | EP | disclosed |
| EP-4097104-A1 | 1H-PYRAZOLO[4,3-D]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS | Bristol-Myers Squibb Company (US) | 2022-12-07 | — | — | EP | disclosed |
| EP-4097103-A1 | 1H-PYRAZOLO[4,3-D]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS | Bristol-Myers Squibb Company (US) | 2022-12-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230127326-A1 | C3-SUBSTITUTED 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS | TLR7, TLR3, TLR9 | F2 2166/4885MAPT 4253/4885KMT2A 3433/4885 |
| US-20230140430-A1 | 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS | TLR7, TLR1, TLR9 | F2 4224/4885MAPT 3546/4885KMT2A 2496/4885 |
| US-20230122249-A1 | 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS | TLR7, TLR9, TLR1 | F2 4300/4885MAPT 3579/4885KMT2A 2364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.